

18 April 2018

### May 2019 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **May 2019** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

#### New listings

- Acarbose (Accarb) tab 50 mg – S29 and wastage claimable (p'code 2402408)
- Clomipramine hydrochloride (Apo-Clomipramine) tab 25 mg – safety medicine; prescriber may determine dispensing frequency (p'code 2565773)
- Cycloserine (Cyclorin) cap 250 mg – Retail pharmacy-Specialist, no patient co-payment payable, S29 and wastage claimable (p'code 2566508)
- Doxycycline (Doxine) tab 100 mg, 500 tab pack – up to 30 tab available on a PSO (p'code 2545136)
- Eftrenonacog alfa [recombinant factor IX] (Alprolix) inj 250 iu vial (p'code 2565846), 500 iu vial (p'code 2565854), 1,000 iu vial (p'code 2565862), 2,000 iu vial (p'code 2565870) and 3,000 iu vial (p'code 2565889) – [Xpharm]
- Heparin sodium (Pfizer) inj 5,000 iu per ml, 1 ml (p'code 2566184)
- Levodopa with carbidopa (Mylan) tab long-acting 100 mg with carbidopa 25 mg – S29 and wastage claimable (p'code 2566168)
- Phenelzine sulphate (Nardil S29) tab 15 mg – S29 and wastage claimable (p'code 2566516)
- Rurioctocog alfa pegol [recombinant factor VIII] (Adynovate) inj 250 iu vial (p'code 2561115), 500 iu vial (p'code 2561123), 1,000 iu vial (p'code 2561131) and 2,000 iu vial (p'code 2561158) – [Xpharm]
- Tetracosactrin (AU Synacthen S29) inj 250 mcg per ml, 1 ml ampoule – S29 and wastage claimable (p'code 2566494)

#### Changes to restrictions, chemical names and presentations

- Diclofenac sodium (Apo-Diclo SR) tab long-acting 75 mg – reinstate stat dispensing
- Eptacog alfa [recombinant factor VIIIA] (NovoSeven RT) inj 1 mg, 2 mg, 5 mg and 8 mg syringe – amended restriction
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 U, 1,000 U and 2,500 U – amended restriction
- Insulin pump (Tandem t:slim X2) min basal rate 0.1 U/h – amended presentation description
- Moroctocog alfa [recombinant factor VIII] (Xyntha) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu prefilled syringe – amended restriction
- Nonacog gamma [recombinant factor IX] [RIXUBIS] inj 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vial – amended restriction

- Octocog alfa [recombinant factor VIII] (Advate) inj 250 iu, 500 iu, 1,000 iu, 1,500 iu, 2,000 iu and 3,000 iu vial – amended restriction
- Octocog alfa [recombinant factor VIII] (Kogenate FS) inj 250 iu, 500 iu, 1,000 iu, 1,500 iu, 2,000 iu and 3,000 iu vial – amended restriction
- Pizotifen (Sandomigran) tab 500 mcg – S29 and wastage claimable removed
- Rivaroxaban (Xarelto) tab 15 mg – PSO restriction added

**Increased subsidy**

Chemical	Presentation	Fully subsidised brands
Trimethoprim with sulphamethoxazole [co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	Trisul
Vinorelbine	Inj 1 mg for ECP	Baxter

**Decreased subsidy**

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Factor eight inhibitor bypassing fraction	Inj 500 U, 1,000 U and 2,500 U	FEIBA NF	
Filgrastim	Inj 300 mcg per 0.5 ml prefilled syringe Inj 480 mcg per 0.5 ml prefilled syringe	Nivestim*	Zarzio
Ibuprofen	Oral liq 20 mg per ml	Ethics*	Fenpaed
Lamotrigine	Tab dispersible 25 mg, 50 mg and 100 mg	Logem Arrow-Lamotrigine* Lamictal*	
Levetiracetam	Tab 250 mg, 500 mg, 750 mg and 1,000 mg	Everet	
Nonacog gamma [recombinant factor IX]	Inj 500 iu vial, 1,000 iu vial, 2,000 iu vial and 3,000 iu vial	RIXUBIS	
Octocog alfa [recombinant factor VIII]	Inj 250 iu vial, 500 iu vial, 1,000 iu vial, 1,500 iu vial, 2,000 iu vial and 3,000 iu vial	Advate	
Oxycodone hydrochloride	Tab controlled-release 5 mg, 10 mg, 20 mg, 40 mg and 80 mg	Oxycodone Sandoz*	BNM
Valganciclovir	Tab 450 mg	Valganciclovir Mylan*	Valcyte
Zoledronic acid	Inj 4 mg per 5 ml, vial	Zoledronic acid Mylan*	Zometa

\* no subsidy changes for these brands for 1 May 2019.